Compounds > 17-alpha-hydroxyprogesterone
Page last updated: 2024-08-17

17-alpha-hydroxyprogesterone and ER-Negative PR-Negative HER2-Negative Breast Cancer

17-alpha-hydroxyprogesterone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
An, W; Cheng, Q; Du, L; Feng, S; He, D; Lin, H; Ma, C; Ma, L; Sun, JP; Wang, C; Wang, M; Wu, X; Xiao, P; Yang, F; Yang, Z; Yu, X; Zhang, C; Zhang, P; Zhang, Z; Zheng, Y; Zhong, Y1

Other Studies

1 other study(ies) available for 17-alpha-hydroxyprogesterone and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Progesterone activates GPR126 to promote breast cancer development via the Gi pathway.
    Proceedings of the National Academy of Sciences of the United States of America, 2022, 04-12, Volume: 119, Issue:15

    Topics: 17-alpha-Hydroxyprogesterone; Cell Line, Tumor; Humans; Progesterone; Receptors, G-Protein-Coupled; Receptors, Progesterone; Signal Transduction; Triple Negative Breast Neoplasms

2022